{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T12:08:00Z","timestamp":1792757280267,"version":"4.5.0"},"reference-count":124,"publisher":"American Society for Microbiology","issue":"3","license":[{"start":{"date-parts":[[2020,2,21]],"date-time":"2020-02-21T00:00:00Z","timestamp":1582243200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2020,2,21]]},"abstract":"<jats:p>Many antibiotics carry caution stickers that warn against alcohol consumption. Data regarding concurrent use are sparse. An awareness of data that address this common clinical scenario is important so health care professionals can make informed clinical decisions and address questions in an evidence-based manner. The purpose of this systematic review was to determine the evidence behind alcohol warnings issued for many common antimicrobials.<\/jats:p>","DOI":"10.1128\/aac.02167-19","type":"journal-article","created":{"date-parts":[[2019,12,23]],"date-time":"2019-12-23T08:26:41Z","timestamp":1577089601000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":54,"title":["Fact versus Fiction: a Review of the Evidence behind Alcohol and Antibiotic Interactions"],"prefix":"10.1128","volume":"64","author":[{"given":"Kari A.","family":"Mergenhagen","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Veterans Affairs Western New York Healthcare System, Buffalo, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bethany A.","family":"Wattengel","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Veterans Affairs Western New York Healthcare System, Buffalo, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan K.","family":"Skelly","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Veterans Affairs Western New York Healthcare System, Buffalo, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Collin M.","family":"Clark","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Veterans Affairs Western New York Healthcare System, Buffalo, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4566-7442","authenticated-orcid":false,"given":"Thomas A.","family":"Russo","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Veterans Affairs Western New York Healthcare System, Buffalo, New York, USA"},{"name":"Department of Medicine, University at Buffalo, Buffalo, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.a2885"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.13766"},{"key":"e_1_3_2_4_2","volume-title":"Outpatient antibiotic prescriptions\u2014United States, 2016","author":"Centers for Disease Control and Prevention","year":"2016","unstructured":"Centers for Disease Control and Prevention. 2016. Outpatient antibiotic prescriptions\u2014United States, 2016. Centers for Disease Control and Prevention, Atlanta, GA."},{"key":"e_1_3_2_5_2","volume-title":"Harmful interactions mixing alcohol with medicines. NIH publication no. 13-5329","author":"National Institute on Alcohol Abuse and Alcoholism","year":"2014","unstructured":"National Institute on Alcohol Abuse and Alcoholism. 2014. Harmful interactions mixing alcohol with medicines. NIH publication no. 13-5329. National Institute on Alcohol Abuse and Alcoholism, Bethesda, MD."},{"key":"e_1_3_2_6_2","unstructured":"U.S. Food and Drug Administration. 2013. Avoid food-drug interactions. U.S. Food and Drug Administration White Oak MD."},{"key":"e_1_3_2_7_2","first-page":"40","article-title":"Alcohol and medication interactions","volume":"23","author":"Weathermon R","year":"1999","unstructured":"Weathermon R, Crabb DW. 1999. Alcohol and medication interactions. Alcohol Res Health 23:40\u201354.","journal-title":"Alcohol Res Health"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjopharm.2007.03.006"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.2174\/187152710790966678"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1177\/0885713X9701200404"},{"key":"e_1_3_2_11_2","first-page":"536","article-title":"Ethanol and the absorption of oral penicillin in man","volume":"25","author":"Lindberg RL","year":"1987","unstructured":"Lindberg RL, Huupponen RK, Viljanen S, Pihlajamaki KK. 1987. Ethanol and the absorption of oral penicillin in man. Int J Clin Pharmacol Ther Toxicol 25:536\u2013538.","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"key":"e_1_3_2_12_2","first-page":"428","article-title":"Amoxicillin kinetics and ethanol ingestion","volume":"26","author":"Morasso MI","year":"1988","unstructured":"Morasso MI, Hip A, Marquez M, Gonzalez C, Arancibia A. 1988. Amoxicillin kinetics and ethanol ingestion. Int J Clin Pharmacol Ther Toxicol 26:428\u2013431.","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2015.07.008"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1530-0277.1999.tb04192.x"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600800602"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.4103\/0253-7613.114991"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.31.9.1328"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(80)91868-1"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.9738\/INTSURG-D-13-00086.1"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.5863\/1551-6776-23.2.168"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-198306000-00013"},{"key":"e_1_3_2_22_2","first-page":"70","article-title":"Disulfiram-like reactions rare with ceftriaxone","volume":"47","author":"Billstein SA","year":"1992","unstructured":"Billstein SA, Sudol TE. 1992. Disulfiram-like reactions rare with ceftriaxone. Geriatrics 47:70.","journal-title":"Geriatrics"},{"key":"e_1_3_2_23_2","first-page":"84","article-title":"Clinical adverse effects during ceftriaxone therapy","volume":"77","author":"Moskovitz BL","year":"1984","unstructured":"Moskovitz BL. 1984. Clinical adverse effects during ceftriaxone therapy. Am J Med 77:84\u201388.","journal-title":"Am J Med"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkg208"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.1.210-219.2006"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.4076\/1757-1626-2-7787"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1177\/106002809402801109"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1086\/511159"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1177\/106002809202600912"},{"key":"e_1_3_2_30_2","first-page":"426","article-title":"Influence of alcohol consumption on erythromycin ethylsuccinate kinetics","volume":"28","author":"Morasso MI","year":"1990","unstructured":"Morasso MI, Chavez J, Gai MN, Arancibia A. 1990. Influence of alcohol consumption on erythromycin ethylsuccinate kinetics. Int J Clin Pharmacol Ther Toxicol 28:426\u2013429.","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"key":"e_1_3_2_31_2","first-page":"582","article-title":"Effects of erythromycin on gastric emptying, alcohol absorption and small intestinal transit in normal subjects","volume":"34","author":"Edelbroek MA","year":"1993","unstructured":"Edelbroek MA, Horowitz M, Wishart JM, Akkermans LM. 1993. Effects of erythromycin on gastric emptying, alcohol absorption and small intestinal transit in normal subjects. J Nucl Med 34:582\u2013588.","journal-title":"J Nucl Med"},{"key":"e_1_3_2_32_2","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/j.1875-9114.1995.tb04350.x","article-title":"Effect of erythromycin on ethanol\u2019s pharmacokinetics and perception of intoxication","volume":"15","author":"Min DI","year":"1995","unstructured":"Min DI, Noormohamed SE, Flanigan MJ. 1995. Effect of erythromycin on ethanol\u2019s pharmacokinetics and perception of intoxication. Pharmacotherapy 15:164\u2013169.","journal-title":"Pharmacotherapy"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1136\/thorax.56.5.398"},{"key":"e_1_3_2_34_2","first-page":"462","article-title":"Influence of ethanol ingestion on tetracycline kinetics","volume":"33","author":"Seitz C","year":"1995","unstructured":"Seitz C, Garcia P, Arancibia A. 1995. Influence of ethanol ingestion on tetracycline kinetics. Int J Clin Pharmacol Ther 33:462\u2013464.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"e_1_3_2_35_2","first-page":"303","article-title":"Effect of long-term alcohol consumption on the half-life of tetracycline and doxycycline in man","volume":"14","author":"Neuvonen PJ","year":"1976","unstructured":"Neuvonen PJ, Penttila O, Roos M, Tirkkonen J. 1976. Effect of long-term alcohol consumption on the half-life of tetracycline and doxycycline in man. Int J Clin Pharmacol Biopharm 14:303\u2013307.","journal-title":"Int J Clin Pharmacol Biopharm"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0773.1982.tb00989.x"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1179\/joc.2005.17.5.509"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2011.03.002"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2017.11.019"},{"key":"e_1_3_2_40_2","unstructured":"Procter and Gamble Pharmaceuticals. 2009. Macrobid-nitrofurantoin package insert. https:\/\/wwwaccessdatafdagov\/drugsatfda_docs\/label\/2009\/020064s019lblpdf."},{"key":"e_1_3_2_41_2","first-page":"1","article-title":"Drug interactions","volume":"4","author":"Azarnoff DL","year":"1970","unstructured":"Azarnoff DL, Hurwitz A. 1970. Drug interactions. Pharmacol Physicians 4:1\u20137.","journal-title":"Pharmacol Physicians"},{"key":"e_1_3_2_42_2","volume-title":"Clinical effects of interaction between drugs","author":"Petrie JDD","year":"1975","unstructured":"Petrie JDD, Howie J. 1975. Drug interaction in general practice. In Cluff LE, Petrie JC (ed), Clinical effects of interaction between drugs. Excerpta Medica, Amsterdam, Netherlands."},{"key":"e_1_3_2_43_2","first-page":"238","article-title":"Food and drug interaction: influence of food on drug bioavailability and toxicity","author":"D\u2019arcy PM","year":"1980","unstructured":"D\u2019arcy PM. 1980. Food and drug interaction: influence of food on drug bioavailability and toxicity. Pharm Int I:238\u2013244.","journal-title":"Pharm Int"},{"key":"e_1_3_2_44_2","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJM198201143060224","article-title":"Clinical drug information: a case of misinformation","volume":"306","author":"Rowles B","year":"1982","unstructured":"Rowles B, Worthen DB. 1982. Clinical drug information: a case of misinformation. N Engl J Med 306:113\u2013114.","journal-title":"N Engl J Med"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0079-6468(08)70446-6"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1136\/sti.56.5.285"},{"key":"e_1_3_2_47_2","volume-title":"Flagyl (metronidazole) (prescribing information)","author":"Pfizer","year":"2018","unstructured":"Pfizer. January 2018. Flagyl (metronidazole) (prescribing information). Pfizer, New York, NY."},{"key":"e_1_3_2_48_2","first-page":"158","article-title":"Metronidazole\u2014a new agent for combined somatic and psychic therapy of alcoholism. a case study and preliminary report","volume":"29","author":"Taylor JA","year":"1964","unstructured":"Taylor JA. 1964. Metronidazole\u2014a new agent for combined somatic and psychic therapy of alcoholism. a case study and preliminary report. Bull Los Angel Neuro Soc 29:158\u2013162.","journal-title":"Bull Los Angel Neuro Soc"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.123.6.722"},{"key":"e_1_3_2_50_2","first-page":"326","article-title":"The use of metronidazole in the treatment of alchoholism. (A further study)","volume":"29","author":"Friedland P","year":"1968","unstructured":"Friedland P, Vaisberg M. 1968. The use of metronidazole in the treatment of alchoholism. (A further study). Dis Nerv Syst 29:326\u2013327.","journal-title":"Dis Nerv Syst"},{"key":"e_1_3_2_51_2","first-page":"43","article-title":"Evaluation of metronidazole in the treatment of alcoholism. A comprehensive three-year study comprising 60 cases","volume":"67","author":"Sansoy OM","year":"1970","unstructured":"Sansoy OM. 1970. Evaluation of metronidazole in the treatment of alcoholism. A comprehensive three-year study comprising 60 cases. Rocky Mt Med J 67:43\u201347.","journal-title":"Rocky Mt Med J"},{"key":"e_1_3_2_52_2","first-page":"419","article-title":"Chemical reduction of the compulsion to drink with metronidazole: a new treatment modality in the therapeutic program of the alcoholic","volume":"9","author":"Lehmann HE","year":"1967","unstructured":"Lehmann HE, Ban TA. 1967. Chemical reduction of the compulsion to drink with metronidazole: a new treatment modality in the therapeutic program of the alcoholic. Curr Ther Res Clin Exp 9:419\u2013428.","journal-title":"Curr Ther Res Clin Exp"},{"key":"e_1_3_2_53_2","doi-asserted-by":"crossref","first-page":"899","DOI":"10.15288\/qjsa.1968.29.899","article-title":"Effect of metronidazole on drinking by alcoholics","volume":"29","author":"Egan WP","year":"1968","unstructured":"Egan WP, Goetz R. 1968. Effect of metronidazole on drinking by alcoholics. Q J Stud Alcohol 29:899\u2013902.","journal-title":"Q J Stud Alcohol"},{"key":"e_1_3_2_54_2","first-page":"82","article-title":"A six-month controlled evaluation of metronidazole (Flagyl) in chronic alcoholic patients","volume":"10","author":"Gallant DM","year":"1968","unstructured":"Gallant DM, Bishop MP, Camp E, Tisdale C. 1968. A six-month controlled evaluation of metronidazole (Flagyl) in chronic alcoholic patients. Curr Ther Res Clin Exp 10:82\u201387.","journal-title":"Curr Ther Res Clin Exp"},{"key":"e_1_3_2_55_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.114.509.473"},{"key":"e_1_3_2_56_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.123.10.1276"},{"key":"e_1_3_2_57_2","doi-asserted-by":"crossref","first-page":"734","DOI":"10.15288\/qjsa.1972.33.734","article-title":"Disulfiramlike effects of trichomonacidal drugs. A review and double-blind study","volume":"33","author":"Goodwin DW","year":"1972","unstructured":"Goodwin DW, Reinhard J. 1972. Disulfiramlike effects of trichomonacidal drugs. A review and double-blind study. Q J Stud Alcohol 33:734\u2013740.","journal-title":"Q J Stud Alcohol"},{"key":"e_1_3_2_58_2","doi-asserted-by":"crossref","first-page":"94","DOI":"10.15288\/qjsa.1972.33.097","article-title":"Phenytoin, metronidazole and multivitamins in the treatment of alcoholism","volume":"33","author":"Kaplan R","year":"1972","unstructured":"Kaplan R, Blume S, Rosenberg S, Pitrelli J, Turner WJ. 1972. Phenytoin, metronidazole and multivitamins in the treatment of alcoholism. Q J Stud Alcohol 33:94\u2013104.","journal-title":"Q J Stud Alcohol"},{"key":"e_1_3_2_59_2","doi-asserted-by":"crossref","first-page":"140","DOI":"10.15288\/qjsa.1969.30.140","article-title":"Metronidazole in the treatment of alcoholism. A clinical trial and review of the literature","volume":"30","author":"Lal S","year":"1969","unstructured":"Lal S. 1969. Metronidazole in the treatment of alcoholism. A clinical trial and review of the literature. Q J Stud Alcohol 30:140\u2013151.","journal-title":"Q J Stud Alcohol"},{"key":"e_1_3_2_60_2","doi-asserted-by":"crossref","first-page":"544","DOI":"10.15288\/qjsa.1967.28.544","article-title":"Metronidazole in the treatment of alcoholism","volume":"28","author":"Linton PH","year":"1967","unstructured":"Linton PH, Hain JD. 1967. Metronidazole in the treatment of alcoholism. Q J Stud Alcohol 28:544\u2013546.","journal-title":"Q J Stud Alcohol"},{"key":"e_1_3_2_61_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.1972.tb01202.x"},{"key":"e_1_3_2_62_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.114.512.859"},{"key":"e_1_3_2_63_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.125.8.1063"},{"key":"e_1_3_2_64_2","first-page":"30","article-title":"Four year follow-up of metronidazole treatment program for alcoholism","volume":"40","author":"Penick SB","year":"1971","unstructured":"Penick SB, Sheldon JB, Templer DI, Carrier RN. 1971. Four year follow-up of metronidazole treatment program for alcoholism. IMS Ind Med Surg 40:30\u201332.","journal-title":"IMS Ind Med Surg"},{"key":"e_1_3_2_65_2","doi-asserted-by":"crossref","first-page":"394","DOI":"10.15288\/qjsa.1970.31.394","article-title":"Metronidazole effect on social drinkers","volume":"31","author":"Strassman HD","year":"1970","unstructured":"Strassman HD, Adams B, Pearson AW. 1970. Metronidazole effect on social drinkers. Q J Stud Alcohol 31:394\u2013398.","journal-title":"Q J Stud Alcohol"},{"key":"e_1_3_2_66_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.119.548.85"},{"key":"e_1_3_2_67_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.1969.tb01109.x"},{"key":"e_1_3_2_68_2","doi-asserted-by":"publisher","DOI":"10.1038\/214190b0"},{"key":"e_1_3_2_69_2","doi-asserted-by":"publisher","DOI":"10.1007\/bf02136791"},{"key":"e_1_3_2_70_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(70)90108-5"},{"key":"e_1_3_2_71_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1530-0277.2000.tb02026.x"},{"key":"e_1_3_2_72_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1A066"},{"key":"e_1_3_2_73_2","volume-title":"Tindamax (tinidazole) (prescribing information)","author":"Mission Pharmacal Company","year":"2007","unstructured":"Mission Pharmacal Company. August 2007. Tindamax (tinidazole) (prescribing information). Mission Pharmacal Company, San Antonio, TX."},{"key":"e_1_3_2_74_2","volume-title":"Solosec (secnidazole) (prescribing information)","author":"Lupin Pharmaceuticals","year":"2017","unstructured":"Lupin Pharmaceuticals. October 2017. Solosec (secnidazole) (prescribing information). Lupin Pharmaceuticals, Baltimore, MD."},{"key":"e_1_3_2_75_2","volume-title":"Bactrim (sulfamethoxazole and trimethoprim) (prescribing information)","author":"Hoffmann-La Roche, Inc","year":"2013","unstructured":"Hoffmann-La Roche, Inc. June 2013. Bactrim (sulfamethoxazole and trimethoprim) (prescribing information). Hoffmann-La Roche, Inc., Philadelphia, PA. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/017377s068s073lbl.pdf."},{"key":"e_1_3_2_76_2","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1002\/j.1875-9114.1998.tb03913.x","article-title":"Disulfiram-cotrimoxazole reaction","volume":"18","author":"Heelon MW","year":"1998","unstructured":"Heelon MW, White M. 1998. Disulfiram-cotrimoxazole reaction. Pharmacotherapy 18:869\u2013870.","journal-title":"Pharmacotherapy"},{"key":"e_1_3_2_77_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.6151.1519"},{"key":"e_1_3_2_78_2","doi-asserted-by":"publisher","DOI":"10.1007\/bf00252254"},{"key":"e_1_3_2_79_2","doi-asserted-by":"publisher","DOI":"10.1007\/bf00252260"},{"key":"e_1_3_2_80_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2362.1971.tb00552.x"},{"key":"e_1_3_2_81_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00431-13"},{"key":"e_1_3_2_82_2","doi-asserted-by":"publisher","DOI":"10.1177\/00912700122010294"},{"key":"e_1_3_2_83_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2004.02186.x"},{"key":"e_1_3_2_84_2","volume-title":"Zyvox (linezolid) (prescribing information)","author":"Pharmacia and Upjohn","year":"2018","unstructured":"Pharmacia and Upjohn. July 2018. Zyvox (linezolid) (prescribing information). Pharmacia and Upjohn, New York, NY."},{"key":"e_1_3_2_85_2","doi-asserted-by":"publisher","DOI":"10.1177\/0884533610368711"},{"key":"e_1_3_2_86_2","first-page":"31","article-title":"On tyramine, food, beverages and the reversible MAO inhibitor moclobemide","volume":"26","author":"Da Prada M","year":"1988","unstructured":"Da Prada M, Zurcher G, Wuthrich I, Haefely WE. 1988. On tyramine, food, beverages and the reversible MAO inhibitor moclobemide. J Neural Transm Suppl 26:31\u201356.","journal-title":"J Neural Transm Suppl"},{"key":"e_1_3_2_87_2","volume-title":"Sivextro (tedizolid) (prescribing information)","author":"Merck","year":"2016","unstructured":"Merck. October 2016. Sivextro (tedizolid) (prescribing information). Merck, Whitehouse Station, NJ."},{"key":"e_1_3_2_88_2","volume-title":"Meal ideas and menus: avoiding high-tyramine foods made easy","author":"Holden K","year":"2006","unstructured":"Holden K. 2006. Meal ideas and menus: avoiding high-tyramine foods made easy. Teva Neuroscience, Inc, Kansas City, MO. https:\/\/www.mc.vanderbilt.edu\/documents\/neurology\/files\/Tyramine%20Menu%20Book%2006227101.pdf."},{"key":"e_1_3_2_89_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-199818020-00001"},{"key":"e_1_3_2_90_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0733-8635(05)70460-5"},{"key":"e_1_3_2_91_2","first-page":"522","article-title":"Interaction of ketoconazole and ethanol","volume":"5","author":"Magnasco AJ","year":"1986","unstructured":"Magnasco AJ, Magnasco LD. 1986. Interaction of ketoconazole and ethanol. Clin Pharm 5:522\u2013523.","journal-title":"Clin Pharm"},{"key":"e_1_3_2_92_2","first-page":"261","article-title":"Ketoconazole treatment of Candida esophagitis\u2014a prospective study of 12 cases","volume":"78","author":"Fazio RA","year":"1983","unstructured":"Fazio RA, Wickremesinghe PC, Arsura EL. 1983. Ketoconazole treatment of Candida esophagitis\u2014a prospective study of 12 cases. Am J Gastroenterol 78:261\u2013264.","journal-title":"Am J Gastroenterol"},{"key":"e_1_3_2_93_2","volume-title":"Fluconazole (prescribing information)","author":"Pfizer","year":"2010","unstructured":"Pfizer. 2010. Fluconazole (prescribing information). Pfizer, New York, NY."},{"key":"e_1_3_2_94_2","unstructured":"Ortho Dermatologics. 2011. Grifulvin V (prescribing information). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/062279s022lbl.pdf."},{"key":"e_1_3_2_95_2","volume-title":"Goodman and Gilman\u2019s the pharmacological basis of therapeutics","author":"Gilman AR","year":"1990","unstructured":"Gilman AR, Nies A. 1990. Goodman and Gilman\u2019s the pharmacological basis of therapeutics, vol 8. Pergamon Press, New York, NY."},{"key":"e_1_3_2_96_2","first-page":"680","article-title":"Griseofulvin therapy of superficial mycoses","volume":"7","author":"Robinson MM","year":"1959","unstructured":"Robinson MM. 1959. Griseofulvin therapy of superficial mycoses. Antibiot Annu 7:680\u2013686.","journal-title":"Antibiot Annu"},{"key":"e_1_3_2_97_2","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1146\/annurev.me.12.020161.000551","article-title":"Untoward reactions to antimicrobial agents. Griseofulvin","volume":"12","author":"Simon HR","year":"1961","unstructured":"Simon HR. 1961. Untoward reactions to antimicrobial agents. Griseofulvin. Annu Rev Med 12:119\u2013120.","journal-title":"Annu Rev Med"},{"key":"e_1_3_2_98_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0196-0644(94)70167-9"},{"key":"e_1_3_2_99_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw376"},{"key":"e_1_3_2_100_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/17.2.288"},{"key":"e_1_3_2_101_2","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a027011"},{"key":"e_1_3_2_102_2","first-page":"349","article-title":"Rifampin-isoniazid therapy of alcoholic and nonalcoholic tuberculous patients in a U.S. Public Health Service Cooperative Therapy Trial","volume":"122","author":"Cross FS","year":"1980","unstructured":"Cross FS, Long MW, Banner AS, Snider DE, Jr. 1980. Rifampin-isoniazid therapy of alcoholic and nonalcoholic tuberculous patients in a U.S. Public Health Service Cooperative Therapy Trial. Am Rev Respir Dis 122:349\u2013353.","journal-title":"Am Rev Respir Dis"},{"key":"e_1_3_2_103_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0962-8479(96)90098-2"},{"key":"e_1_3_2_104_2","doi-asserted-by":"publisher","DOI":"10.11604\/pamj.2016.25.167.10060"},{"key":"e_1_3_2_105_2","volume-title":"Rifadin (rifampin) (prescribing information)","author":"Sanofi-Aventis","year":"2019","unstructured":"Sanofi-Aventis. 2019. Rifadin (rifampin) (prescribing information). Sanofi-Aventis, Bridgewater, NJ. http:\/\/products.sanofi.us\/rifadin\/Rifadin.pdf."},{"key":"e_1_3_2_106_2","first-page":"991","article-title":"Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study","volume":"117","author":"Kopanoff DE","year":"1978","unstructured":"Kopanoff DE, Snider DE, Jr, Caras GJ. 1978. Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study. Am Rev Respir Dis 117:991\u20131001.","journal-title":"Am Rev Respir Dis"},{"key":"e_1_3_2_107_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0773.1986.tb00114.x"},{"key":"e_1_3_2_108_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007611-198506000-00025"},{"key":"e_1_3_2_109_2","first-page":"29","article-title":"Drug-alcohol interactions: a review of three therapeutic classes","volume":"35","author":"Noureldin M","year":"2010","unstructured":"Noureldin M, Kj JL, Tran M. 2010. Drug-alcohol interactions: a review of three therapeutic classes. US Pharmacist 35:29\u201333.","journal-title":"US Pharmacist"},{"key":"e_1_3_2_110_2","doi-asserted-by":"publisher","DOI":"10.1177\/106002808201600718"},{"key":"e_1_3_2_111_2","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.44.1120"},{"key":"e_1_3_2_112_2","doi-asserted-by":"publisher","DOI":"10.1159\/000448759"},{"key":"e_1_3_2_113_2","volume-title":"Myambutol (ethambutol) (prescribing information)","author":"Patheon Inc","year":"2007","unstructured":"Patheon Inc. January 2007. Myambutol (ethambutol) (prescribing information). Patheon Inc, Toronto, Canada. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/016320s063lbl.pdf."},{"key":"e_1_3_2_114_2","volume-title":"Trecator (ethionamide) (prescribing information)","author":"Wyeth Pharmaceuticals","year":"2018","unstructured":"Wyeth Pharmaceuticals. April 2018. Trecator (ethionamide) (prescribing information). Wyeth Pharmaceuticals Inc, Philadelphia, PA. https:\/\/www.pfizermedicalinformation.com\/en-us\/trecator."},{"key":"e_1_3_2_115_2","first-page":"635","article-title":"Evaluation of the hepatotoxic effect of antituberculous drugs in tuberculosis patients abusing alcohol","volume":"9","author":"Gryminski J","year":"1970","unstructured":"Gryminski J, Lyczewska J, Styszewska H, Walczak J. 1970. Evaluation of the hepatotoxic effect of antituberculous drugs in tuberculosis patients abusing alcohol. Pol Med J 9:635\u2013644.","journal-title":"Pol Med J"},{"key":"e_1_3_2_116_2","doi-asserted-by":"publisher","DOI":"10.1164\/arrd.1967.95.6.1053"},{"key":"e_1_3_2_117_2","volume-title":"Pyrazinamide (prescribing information)","author":"Par Pharmaceutical","year":"2018","unstructured":"Par Pharmaceutical. July 2018. Pyrazinamide (prescribing information). Par Pharmaceutical, Columbus, Ohio."},{"key":"e_1_3_2_118_2","first-page":"995","article-title":"Risk factors for hepatotoxicity associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection: experience from three public health tuberculosis clinics","volume":"6","author":"Lee AM","year":"2002","unstructured":"Lee AM, Mennone JZ, Jones RC, Paul WS. 2002. Risk factors for hepatotoxicity associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection: experience from three public health tuberculosis clinics. Int J Tuber Lung Dis 6:995\u20131000.","journal-title":"Int J Tuber Lung Dis"},{"key":"e_1_3_2_119_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200604-571ST"},{"key":"e_1_3_2_120_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-015-3882-5"},{"key":"e_1_3_2_121_2","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2015.41"},{"key":"e_1_3_2_122_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-011-2254-z"},{"key":"e_1_3_2_123_2","volume-title":"Seromycin (cycloserine) (prescribing information)","author":"Lilly","year":"2005","unstructured":"Lilly. April 2005. Seromycin (cycloserine) (prescribing information). Lilly, Indianapolis, IN."},{"key":"e_1_3_2_124_2","volume-title":"Gris-PEG (griseofluvin) (prescribing information)","author":"Valeant Pharmaceuticals","year":"2016","unstructured":"Valeant Pharmaceuticals. April 2016. Gris-PEG (griseofluvin) (prescribing information). Valeant Pharmaceuticals, Bridgewater, NJ."},{"key":"e_1_3_2_125_2","volume-title":"Isoniazid prescribing information","author":"Epic Pharma","year":"2016","unstructured":"Epic Pharma. 2016. Isoniazid prescribing information. Epic Pharma, Laurelton, NY."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02167-19","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02167-19","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,28]],"date-time":"2024-07-28T22:23:18Z","timestamp":1722205398000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.02167-19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,21]]},"references-count":124,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,2,21]]}},"alternative-id":["10.1128\/AAC.02167-19"],"URL":"https:\/\/doi.org\/10.1128\/aac.02167-19","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,21]]},"assertion":[{"value":"2020-02-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e02167-19"}}